News >

Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC

Published: Monday, Oct 17, 2016

Daniel Heinrich, MD

Daniel Heinrich, MD

Men with bone-metastatic castration-resistant prostate cancer (mCRPC) appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.1

Neither denosumab nor bisphosphonates added to the toxicity of radium-223 alone. The overall rate of adverse events, as well as rates of grade 3/4 adverse events, serious adverse events, and adverse events leading to discontinuation, was similar among patients who received radium-223 alone or with either type of bone-modifying agent.


  1. Saad F, Heidenreich A, Heinrich D, et al. Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP). Presented at: 2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 750P.
  2. Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306-1316.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication